Synaffix Expands Partnership Horizon with Boehringer Ingelheim
January 9, 2025 - 17:10
In a significant move to enhance its portfolio, Synaffix, a leader in antibody-drug conjugate (ADC) technology, has entered into a new licensing agreement with Boehringer Ingelheim. This partnership allows Boehringer to leverage Synaffix's advanced ADC technologies for a specified number of cancer targets, although the exact details regarding the number of targets remain confidential.
This agreement marks a strategic step for Synaffix as it continues to build on its momentum from last year, when it secured several partnerships. Additionally, Synaffix has expanded its collaboration network by forming a technology licensing deal with Mitsubishi Tanabe Pharma in Japan. These developments underscore Synaffix's commitment to advancing cancer treatment options through innovative ADC technologies.
As the landscape of cancer therapeutics evolves, this collaboration with Boehringer Ingelheim is poised to accelerate the development of novel ADC therapies, potentially leading to more effective treatment solutions for patients battling cancer.
MORE NEWS
May 18, 2026 - 09:28
How Space Exploration Leads to New Technology and Scientific InnovationThe quest to explore beyond Earth has quietly reshaped the technology people rely on daily. While astronauts and rovers capture headlines, the real impact often shows up in unexpected places. GPS...
May 17, 2026 - 19:03
Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced TechnologyAsset owners no longer have to rely on outdated GPS pings or hope that a pricey piece of equipment will stay put. Derek Advanced Tracking Systems has rolled out a new generation of monitoring tools...
May 17, 2026 - 04:33
Institutional investors boost Micron Technology, Intel stocks in Q1Institutional investors significantly increased their exposure to Micron Technology and Intel during the first quarter of 2026, signaling renewed confidence in the semiconductor sector. Data shows...
May 16, 2026 - 00:04
ASU joins Applied Materials' EPIC Center as inaugural university research partnerWhen the United States decided in 2020 to reinvest in domestic semiconductor manufacturing, it faced a paradox built into capitalism itself. How do you create the collaborative environment needed...